All-In

Bill Gurley

Bill Gurley argues COVID-19—15 million deaths and $45 trillion in losses—broke the established catastrophe-investigation pattern, despite being 3,000 times larger than five cited disasters.His CAPA framework points to the missing search for root cause, including the DEFUSE proposal rated “highest-tier evidence class,” while he declines to name an origin and warns another pandemic could be handled worse.

Chamath Palihapitiya × Jason Calacanis × David Sacks × David Friedberg × Dr. Mehmet Oz

Healthcare is framed as productive capital: one extra working year for the average American could be worth $3 trillion, while lower-cost care—not simply more spending—is the prerequisite.Negotiated GLP-1 prices could fall from about $1,200 to near $200 and repay taxpayers within two years, while AI may make GPs five to 10 times more efficient.The upside depends on hybrid deployment, interoperability and verification, as suspected hospice and home-care fraud could reach $3.5 billion in Los Angeles County and 20%–30% overall.

David Friedberg × Marty Makary

FDA’s reform agenda targets development speed through centralized reviews, AI completeness checks, one pivotal trial, and fewer animal-testing requirements, potentially saving some companies $100 million to $300 million.Continuous evidence, computational models, and bespoke pathways for cell and gene therapies could increase portfolio throughput while detecting safety signals earlier than conventional review cycles.The competitive test is whether faster U.S. trials can close China’s biotech gap without sacrificing trust, as vaccine, food, pricing, and enforcement reforms remain politically contested.

Chamath Palihapitiya × Jason Calacanis × David Sacks × David Friedberg

The $100K H-1B fee could reset a lottery serving roughly five times the 85,000 annual slots, pricing out labor arbitrage concentrated in IT consulting while remaining about $15K yearly over seven years for scarce talent.Meanwhile, AI efficiency claims, China-focused recruitment, and California’s SB 771 create catalysts and risks to monitor, but Sacks questions the papers’ reproducibility and expects the robot revolution to require more electricity.

Mark Cuban × Tucker Carlson

Cost Plus Drugs exposes extreme pricing gaps by publishing drug costs, adding 15%, and charging $5 each for shipping and pharmacist review, with customers reporting $21 bills instead of $900-$2,000 quotes.PBM formularies control access for more than 180 million people and can block manufacturers from supplying Cost Plus, while the ACA subsidy cliff could raise premiums for 12.5 million people, making transparency, reform, and political execution key risks to monitor.

David Friedberg × Rand Paul

Rand Paul argues tariffs are an additional tax that cannot repair a roughly $2 trillion annual deficit, with projected revenue dwarfed by approximately $15 trillion of borrowing.He opposed a $5 trillion debt-ceiling increase and warns that rising interest costs could make Social Security and Medicare checks arrive while losing purchasing power.Paul expects AI to raise productivity but potentially overbuild data centers, while protectionism could weaken US competitiveness and push China and others toward alternatives to the dollar.

Chamath Palihapitiya × Jason Calacanis × David Sacks × David Friedberg

Trump’s challenge to Lisa Cook tests central-bank independence, while the panel debated replacing Fed rate-setting with market signals and preserving supervision and payments.The 10% Intel stake converts $8-9 billion of CHIPS support into taxpayer upside, as 446 bankruptcies and $2.2 trillion of maturing commercial-real-estate debt expose refinancing risk.

Chamath Palihapitiya × Jason Calacanis × David Sacks × David Friedberg × Ben Shapiro

Trump’s Middle East tour paired roughly $2 trillion of Gulf commitments with AI, aviation and defense deals, positioning Saudi Arabia and Qatar as a strategic platform against China’s influence.The China tariff pause and pharma order offer political wins but leave regulatory parity, counterparty verification and drug-development economics unresolved, while the House tax bill raises a sharper debt and Treasury-yield risk.